Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sosei Group ( (JP:4565) ) has shared an update.
Nxera Pharma’s partner Neurocrine Biosciences has dosed the first patient in a Phase 2 trial of NBI-1117570, an investigational oral dual muscarinic M1/M4 receptor agonist for adults with schizophrenia, triggering US$22.5 million in milestone payments to Nxera that will be booked as revenue in the first quarter of fiscal 2026. The double-blind, placebo-controlled study will enroll about 120 in-patients, assessing changes in the PANSS total score and tracking treatment-emergent adverse events, underscoring the partners’ push to address a major unmet need in schizophrenia and further validating Nxera’s NxWave discovery platform and its muscarinic agonist pipeline.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen1400.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing specialty medicines for patients with unmet medical needs in Japan and globally. It runs an agile commercial business in Japan and the broader APAC region, supported by its proprietary NxWave GPCR structure-based drug discovery platform, and operates from hubs in Japan, the UK, Switzerland and South Korea.
YTD Price Performance: 23.46%
Average Trading Volume: 874,055
Technical Sentiment Signal: Sell
Current Market Cap: Yen92.4B
For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.